Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
Journal of Cutaneous Medicine and Surgery · 2024
DOI: 10.1177/12034754241265696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Medicine and Surgery, 2024. Verfasst von Scott Strum und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Division of Medical Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Skin Neoplasms, Antibodies, Monoclonal, Humanized, Carcinoma, Squamous Cell, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer in Canada. However, few real-world reports exist on the treatment of refractory locally advanced (LA) and metastatic cSCC with cemiplimab to date.
Objectives
The objective of this study was to characterize the demographic and clinical outcomes of advanced cSCC patients on cemiplimab in a real-world setting.
Methods
Retrospective analysis of adult patients with refractory LA and metastatic cSCC treated with cemiplimab at the London Regional Cancer Program in Canada. Patient demographics and treatment characteristics were reported, as well as Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).
Results
Forty patients were included in this study. Sixteen (40%) had LA disease and 24 (60%) had metastatic disease. Median treatment duration was 3.5 months (range: 0.6-29.4 months). Kaplan-Meier analyses of the entire study population revealed that the median OS was not reached [NR; 95% confidence interval (CI) 9.1 months-NR], but median PFS was 11.5 months (95% CI 7.0 months-NR). A total of 25% of patients experienced at least one adverse event from cemiplimab. Reasons for treatment discontinuation were death from any cause (25%), disease progression (15%), cemiplimab adverse events (5%), and other causes (15%).
Discussion
The 12 month estimates of OS and PFS were lower than pivotal phase I and II clinical trials. However, toxicity was tolerable. Cemiplimab remains a safe and effective therapy in patients with refractory LA and metastatic cSCC disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Division of Medical Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
- London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
- Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
ORCID-Profile: Scott Strum, Scott Ernst
Zitieren
APA
Strum, S., Climans, S., Purcell, V., Black, M., Winquist, E., & Ernst, S. (2024). Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754241265696
Vancouver
Strum S, Climans S, Purcell V, Black M, Winquist E, Ernst S. Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma. Journal of Cutaneous Medicine and Surgery. 2024. doi:10.1177/12034754241265696
BibTeX
@article{Strum2024,
author = {Strum, Scott and Climans, Seth and Purcell, Victoria and Black, Morgan and Winquist, Eric and Ernst, Scott},
title = {Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma},
journal = {Journal of Cutaneous Medicine and Surgery},
year = {2024},
doi = {10.1177/12034754241265696}
}
EUVIMED